Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
The average 30-year mortgage rate slipped to 6.18% just before Christmas, offering a small break from last year’s higher levels. Yet despite the improvement, mortgage applications for purchases and refinances have fallen to a three‑month low as buyers remain cautious. With mixed rate movements, fluctuating Treasury yields, and affordability challenges still weighing on first‑time buyers, the market is showing signs of stability but not momentum. Real estate professionals who stay informed on these shifting conditions will be best positioned to guide clients in 2026.
New CoStar data shows a widening split in the U.S. commercial real estate market, with high-value office towers, industrial hubs and major retail assets posting steady gains while smaller properties in secondary markets continue to lose ground. Premium assets logged their sixth straight monthly price increase in November, boosted by falling interest rates and limited new construction, while lower‑tier properties saw continued price declines and weakening demand.
Microsoft has eliminated long‑standing volume discounts on cloud services like Microsoft 365, Power BI, Intune and Defender, meaning healthcare organizations will soon pay the same price per seat whether they purchase 100 or 10,000 licenses. With the change taking effect at renewal, hospitals and health systems must begin auditing unused licenses, right‑sizing staff tiers, and re‑evaluating digital workflows to avoid major cost spikes. CDW is stepping in with advisory support, cost‑optimization tools, and flexible CSP options to help organizations navigate the transition before budgets tighten further.
America is still short nearly 2.8 million homes, and in 2026 the states driving the bulk of new construction are once again Florida and Texas. With the South producing more than half of all new building permits nationwide, these regions are shaping the future of inventory, affordability, and opportunity. For real estate, mortgage, insurance, and finance professionals, the surge in Southern homebuilding—especially in Florida—signals expanding career potential as new inventory enters the market and demand for licensed experts continues to rise.
A new Redfin report crowns Irondequoit, New York as the nation’s most competitive housing market, with homes selling in just 8.5 days and often above asking. Priced at a median of $249,132, the lakeside suburb is drawing buyers seeking affordability and speed. The surprising lineup of competing markets—from Bay Area tech hubs to Rust Belt metros—highlights a shifting post‑pandemic housing landscape where affordability pressures and regional disparities continue to shape buyer behavior.
Alaska has overhauled its Third Party Administrator licensing rules, eliminating major long‑standing exemptions and pulling many previously exempt organizations into full licensing requirements starting January 1, 2026. Under Senate Bill 132 and Bulletin B 25‑09, TPAs must now review their operations, prepare documentation, and monitor upcoming state guidance as Alaska moves toward stricter oversight and stronger consumer protection.
